FindMyKOL
Clinical trialNCT07072585Not, yet, recruitingPhase 2/PHASE3Interventional

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

SponsorChildren's Oncology GroupEnrollment1,708Stage II T Lymphoblastic Leukemia/LymphomaStage III T Lymphoblastic Leukemia/LymphomaStage IV T Lymphoblastic Leukemia/LymphomaT Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bortezomib →Calaspargase pegol →Cyclophosphamide →Cytarabine →Daratumumab →Daunorubicin →Dexamethasone →Doxorubicin →Mercaptopurine →Methotrexate →Methylprednisolone →NelarabinePegaspargase →Prednisolone →Prednisone →Therapeutic hydrocortisoneThioguanineVincristine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Aug 2026
Primary completion
1 Sept 2035
Completion
1 Sept 2035
Last update posted
30 Jul 2026
Registered enrollment
1,708
Registry id
NCT07072585
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.